Australia's most trusted
source of pharma news
Wednesday, 18 March 2026
Posted 17 March 2026 PM
CSL Seqirus' flu vaccine, Fluad, has won TGA approval for adults aged 50 to 64 and will be available on private script, just in time for the upcoming flu season.
An adjuvanted influenza vaccine, Fluad has been funded in Australia since 2018 for adults aged 65 and over on the National Immunisation Program.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.